Johnson & Johnson agrees to acquire Ambrx Biopharma for $2bn

Johnson & Johnson (J&J) has signed a definitive agreement for the acquisition of Ambrx Biopharma in a cash deal valued at $2bn.

Jan 9, 2024 - 18:00

Johnson & Johnson agrees to acquire Ambrx Biopharma for $2bn

Johnson & Johnson (J&J) has signed a definitive agreement for the acquisition of Ambrx Biopharma in a cash deal valued at $2bn.

Read the original article

Tags:

Previous Article

EC approves Pfizer’s Talzenna combo for prostate cancer treatment

HH-006 by Huahui Health for Hepatitis D: Likelihood of Approval

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

Biotech layoffs, slumping stocks, and a 2024 preview

Jan 18, 2024

The return of biotech’s “bump factor” amid an economic downturn

The return of biotech’s “bump factor” amid an economic ...

Nov 17, 2023

STAT+: Amazon’s chief medical officers on where the company’s health care bets are headed next

STAT+: Amazon’s chief medical officers on where the com...

Sep 8, 2023